Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 3, 2014, Pages 402-408.e1

  Saad, Ayman ^a   Mahindra, Anuj ^b   Zhang, Mei Jie ^c   Zhong, Xiaobo ^c   Costa, Luciano J ^d   Dispenzieri, Angela ^e   Drobyski, William R ^c   Freytes, Cesar O ^f   Gale, Robert Peter ^g   Gasparetto, Cristina J ^h   Holmberg, Leona A ⁱ   Kamble, Rammurti T ^j   Krishnan, Amrita Y ^k   Kyle, Robert A ^e   Marks, David ^l   Nishihori, Taiga ^m   Pasquini, Marcelo C ^c   Ramanathan, Muthalagu ⁿ   Lonial, Sagar ^o   Savani, Bipin N ^p   Saber, Wael ^c   Sharma, Manish ^q   Sorror, Mohamed L ⁱ   Wirk, Baldeep M ^r   Hari, Parameswaran N ^c   more..

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e MAYO CLINIC ROCHESTER   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

^j CENTER FOR CELL AND GENE THERAPY   (United States)

^k CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^l BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^m H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁿ UMASS MEMORIAL MEDICAL CENTER   (United States)

^o EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^q THOMAS JEFFERSON UNIVERSITY   (United States)

^r STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Autologous hematopoietic cell transplantation; Comorbidity; Multiple myeloma; Transplant outcome

Indexed keywords

IMMUNOGLOBULIN A; MELPHALAN;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC CELL TRANSPLANT COMORBIDITY INDEX; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION; COMORBIDITY; MULTIPLE MYELOMA; TRANSPLANT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; MYELOABLATIVE AGONISTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84896811241     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.12.557     Document Type: Article

References (18)

1. Harousseau J.L., Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. NEngl J Med 2009, 360:2645-2654.
2. Harousseau J.L. How to select among available options for the treatment of multiple myeloma. Ann Oncol 2012, 23(Suppl 10):334-338.
3. Rajkumar S.V., Sonneveld P. Front-line treatment in younger patients with multiple myeloma. Semin Hematol 2009, 46:118-126.
4. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000, 36:453-471.
5. Farina L., Bruno B., Patriarca F., et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 2009, 23:1131-1138.
6. Pollack S.M., Steinberg S.M., Odom J., et al. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:223-230.
7. Sorror M., Storer B., Sandmaier B.M., et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008, 112:1992-2001.
8. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
9. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004, 104:961-968.
10. Sorror M.L. How I assess comorbidities before hematopoietic cell transplantation. Blood 2013, 121:2854-2863.
11. Terpos E., Cibeira M.T., Blade J., Ludwig H. Management of complications in multiple myeloma. Semin Hematol 2009, 46:176-189.
12. Guilfoyle R., Demers A., Bredeson C., et al. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 2009, 43:133-139.
13. Attal M., Harousseau J.L., Stoppa A.M., et al. Aprospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. NEngl J Med 1996, 335:91-97.
14. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. NEngl J Med 2003, 348:1875-1883.
15. Labonte L., Iqbal T., Zaidi M.A., et al. Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008, 14:1039-1044.
16. Sorror M., Storer B., Gopal A. Comorbidity, lactate dehydrogenase (LDH), and chemosensitivity are independent predictors of mortality after autologous hematopoietic cell transplantation (HCT) for patients (pts) with lymphoma. Blood 2007, 110(Part 1):no. 616 [abstract].
17. Wildes T.M., Augustin K.M., Sempek D., et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:840-846.
18. Ludwig H., Durie B.G., Bolejack V., et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008, 111:4039-4047.